Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study
ConclusionLedipasvir/sofosbuvir with ribavirin is an effective retreatment option for patients with chronic hepatitis C who failed to respond to prior daclatasvir and asunaprevir therapy.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research
More News: Cirrhosis | Gastroenterology | Hepatitis | Hepatitis C | Japan Health | Liver | Study | Urology & Nephrology | Virology